- Hem
- Om universitetet
- Hitta person
- Chiara Timperanza
Chiara Timperanza
-
Modified poly-L-lysine for use as a clearing agent in pretargeted
radioimmunotherapy
Chiara Timperanza, Anna Gustafsson-Lutz, Tom Bäck, Damian J. Green, Sture Lindegren, Emma Aneheim
EJNMMI RADIOPHARMACY AND CHEMISTRY - 2024 -
In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with
astatine-211
Chiara Timperanza, Holger Jensen, Ellinor Hansson, Tom Bäck, Sture Lindegren, Emma Aneheim
EJNMMI RADIOPHARMACY AND CHEMISTRY - 2024 -
Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation
recovery
Emma Aneheim, Ellinor Hansson, Chiara Timperanza, Holger Jensen, Sture Lindegren
SCIENTIFIC REPORTS - 2024 -
Astatine-211 based radionuclide therapy: Current clinical trial
landscape
Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, K. Smerud, Stig Palm
Frontiers in Medicine - 2023 -
Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and
Astatine-211
Chiara Timperanza, H. Jensen, Tom Bäck, Sture Lindegren, Emma Aneheim
Pharmaceuticals - 2023